Table of Contents

Research Articles

• Research Articles

  Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy

  Else Driehuis, Sigrid Kolders, Sacha Spelier, Kadi Lõhmussaar, Stefan M. Willems, Lot A. Devriese, Remco de Bree, Emma J. de Ruiter, Jeroen Korving, Harry Begthel, Johan H. van Es, Veerle Geurts, Gui-Wei He, Richard H. van Jaarsveld, Rurika Oka, Mauro J. Muraro, Judith Vivié, Maurice M.J.M. Zandvliet, Antoni P.A. Hendrickx, Nino Iakobachvili, Priya Sridevi, Onno Kranenburg, Ruben van Boxtel, Geert J.P.L. Kops, David A. Tuveson, Peter J. Peters, Alexander van Oudenaarden and Hans Clevers

  Cancer Discov July 1 2019 9 (7) 852-871; DOI:10.1158/2159-8290.CD-18-1522

  
  

  Organoids derived from head and neck squamous cell carcinoma (HNSCC) and matching normal tissue allow for the in vitro characterization of the genetics, histology, and drug sensitivity of HNSCC.

• Research Articles

  Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML

  Cihangir Duy, Matt Teater, Francine E. Garrett-Bakelman, Tak C. Lee, Cem Meydan, Jacob L. Glass, Meng Li, Johannes C. Hellmuth, Helai P. Mohammad, Kimberly N. Smitheman, Alan H. Shih, Omar Abdel-Wahab, Martin S. Tallman, Monica L. Guzman, David Muench, H. Leighton Grimes, Gail J. Roboz, Ryan G. Kruger, Caretha L. Creasy, Elisabeth M. Paietta, Ross L. Levine, Martin Carroll and Ari M. Melnick

  Cancer Discov July 1 2019 9 (7) 872-889; DOI:10.1158/2159-8290.CD-19-0106

  
  

  Analysis of a long-term primary acute myeloid leukemia (AML) ex vivo culture platform shows that combined targeting of enhancers with an LSD1 inhibitor and promoters with 5-azacytidine shows greater efficacy than monotherapy, particularly in TET2-mutant AML.

• Research Articles

  Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment

  Xufeng Chen, Christina Glytsou, Hua Zhou, Sonali Narang, Denis E. Reyna, Andrea Lopez, Theodore Sakellaropoulos, Yixiao Gong, Andreas Kloetgen, Yoon Sing Yap, Eric Wang, Evripidis Gavathiotis, Aristotelis Tsirigos, Raoul Tibes and Iannis Aifantis

  Cancer Discov July 1 2019 9 (7) 890-909; DOI:10.1158/2159-8290.CD-19-0117

  
  

  Depletion of mitochondrial proteins involved in maintenance of mitochondrial function and structure including the chaperonin CLPB is synthetically lethal with venetoclax in acute myeloid leukemia cells.

• Research Articles

  The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells

  Tamilla Nechiporuk, Stephen E. Kurtz, Olga Nikolova, Tingting Liu, Courtney L. Jones, Angelo D'Alessandro, Rachel Culp-Hill, Amanda d'Almeida, Sunil K. Joshi, Mara Rosenberg, Cristina E. Tognon, Alexey V. Danilov, Brian J. Druker, Bill H. Chang, Shannon K McWeeney and Jeffrey W. Tyner

  Cancer Discov July 1 2019 9 (7) 910-925; DOI:10.1158/2159-8290.CD-19-0125

  
  

  Inactivation of p53 and proapoptotic proteins promotes resistance to venetoclax in acute myeloid leukemia by inducing changes in mitochondrial homeostasis and cellular metabolism.

• Research Articles

  Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

  Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J.H. De Clercq, Man Xu, Stephen Wang, Michael D. Cameron, David E. Heppner, Bo Hee Shin, Thomas W. Gero, Annan Yang, Suzanne E. Dahlberg, Kwok-Kin Wong, Michael J. Eck, Nathanael S. Gray and Pasi A. Jänne

  Cancer Discov July 1 2019 9 (7) 926-943; DOI:10.1158/2159-8290.CD-18-0903

  
  

  An allosteric inhibitor of mutant EGFR is effective against common resistance mutations alone or in combination with mutant-selective ATP-competitive EGFR inhibitors.

• Research Articles

  Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents

  Chen Lossos, Yunpeng Liu, Kellie E. Kolb, Amanda L. Christie, Alexandria Van Scoyk, Sanjay M. Prakadan, Kay Shigemori, Kristen E. Stevenson, Sara Morrow, Olivia D. Plana, Cameron Fraser, Kristen L. Jones, Huiyun Liu, Christian P. Pallasch, Rebecca Modiste, Quang-De Nguyen, Jeffrey W. Craig, Elizabeth A. Morgan, Francisco Vega, Jon C. Aster, Kristopher A. Sarosiek, Alex K. Shalek, Michael T. Hemann and David M. Weinstock

  Cancer Discov July 1 2019 9 (7) 944-961; DOI:10.1158/2159-8290.CD-18-1393

  
  

  Analysis of in vivo models of double-hit lymphoma reveals the molecular mechanism underlying the role of cyclophosphamide and other alkylating agents on tumor clearance and antibody resistance.

• Research Articles | AuthorChoice

  A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1

  Evangelia Loizou, Ana Banito, Geulah Livshits, Yu-Jui Ho, Richard P. Koche, Francisco J. Sánchez-Rivera, Allison Mayle, Chi-Chao Chen, Savvas Kinalis, Frederik O. Bagger, Edward R. Kastenhuber, Benjamin H. Durham and Scott W. Lowe

  Cancer Discov July 1 2019 9 (7) 962-979; DOI:10.1158/2159-8290.CD-18-1391

  
  

  The gain-of-function mutant p53^R172H upregulates the transcription factor FOXH1 to promote self-renewal in acute myeloid leukemia.